التفاصيل البيبلوغرافية
| العنوان: |
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) |
| المؤلفون: |
de Groot, Stefanie, Pijl, Hanno, Charehbili, AyoubAff1, Aff5, van de Ven, Saskia, Smit, Vincent T. H. B. M., Meershoek-Klein Kranenbarg, Elma, Heijns, Joan B., van Warmerdam, Laurence J. C., Kessels, Lonneke W., Dercksen, M. Wouter, Pepels, Manon J. A. E., van Laarhoven, Hanneke W. M., Vriens, Birgit E. P. J., Putter, Hein, Fiocco, MartaAff12, Aff13, Liefers, Gerrit-Jan, van der Hoeven, Jacobus J. M.Aff1, Aff14, Nortier, Johan W. R., Kroep, Judith R.Aff1, on behalf of the Dutch Breast Cancer Research GroupAff15 |
| المصدر: |
Breast Cancer Research. 21(1) |
| قاعدة البيانات: |
Springer Nature Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder